Abstract
Purpose
To investigate the in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) outcomes and identify factors that might affect live births in patients with early-stage endometrial cancer (EEC) and atypical endometrial hyperplasia (AEH).
Methods
This retrospective study was performed in a tertiary hospital. Patients (n = 123) with EEC or AEH, who underwent IVF/ICSI treatment between January 2010 and December 2019, were divided into a live birth group and a non-live birth group. Clinical characteristics and IVF/ICSI outcomes were assessed.
Results
A total of 123 patients (28 with EEC and 95 with AEH) underwent 215 ovarian stimulation cycles, resulting in 121 fresh embryo transfer (ET) and 108 frozen-thawed ET. Among 229 ET cycles, 91 (23.7%) of 384 embryos were implanted and 86 pregnancies were achieved, including five ectopic pregnancies (5.8%), 28 miscarriages (32.6%), and 53 live births (61.6%). The clinical pregnancy and live birth rates in each ET cycle were 37.6% and 23.1%, respectively. Fifty-one patients gave birth to 57 live neonates, and the cumulative live birth rate was 41.46%. Multiple logistic regression analysis showed that maternal age, histological type, thin endometrium, and time after complete remission (CR) to IVF cycle started were significantly associated with live births.
Conclusions
The live birth rate after IVF/ICSI is promising in infertile patients with EEC and AEH. A shorter interval between CR and IVF/ICSI treatment might be a positive factor, while age > 35 years, endometrial thickness < 8 mm on the day of ET, and degree of endometrial lesion progressing into carcinoma can negatively influence IVF/ICSI outcomes.
Similar content being viewed by others
Data availability
All data generated and analyzed during this study are available from the corresponding author on reasonable request.
References
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. https://doi.org/10.3322/caac.21660.
Lucchini SM, Esteban A, Nigra MA, et al. Updates on conservative management of endometrial cancer in patients younger than 45 years. Gynecol Oncol. 2021;161:802–9. https://doi.org/10.1016/j.ygyno.2021.04.017.
Lacey JV Jr, Chia VM. Endometrial hyperplasia and the risk of progression to carcinoma. Maturitas. 2009;63:39–44. https://doi.org/10.1016/j.maturitas.2009.02.005.
Koh WJ, Abu-Rustum NR, Bean S, et al. Uterine neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018;16:170–99. https://doi.org/10.6004/jnccn.2018.0006.
Concin N, Creutzberg CL, Vergote I, et al. ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma. Virchows Arch. 2021;478:153–90. https://doi.org/10.1007/s00428-020-03007-z.
Corzo C, Barrientos Santillan N, Westin SN, Ramirez PT. Updates on conservative management of endometrial cancer. J Minim Invasive Gynecol. 2018;25:308–13. https://doi.org/10.1016/j.jmig.2017.07.022.
Gunderson CC, Fader AN, Carson KA, Bristow RE. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol. 2012;125:477–82. https://doi.org/10.1016/j.ygyno.2012.01.003.
Ohyagi-Hara C, Sawada K, Aki I, et al. Efficacies and pregnant outcomes of fertility-sparing treatment with medroxyprogesterone acetate for endometrioid adenocarcinoma and complex atypical hyperplasia: our experience and a review of the literature. Arch Gynecol Obstet. 2015;291:151–7. https://doi.org/10.1007/s00404-014-3417-z.
Zhou H, Cao D, Yang J, et al. Gonadotropin-releasing hormone agonist combined with a levonorgestrel-releasing intrauterine system or letrozole for fertility-preserving treatment of endometrial carcinoma and complex atypical hyperplasia in young Women. Int J Gynecol Cancer. 2017;27:1178–82. https://doi.org/10.1007/s00404-014-3417-z.
Leone Roberti Maggiore U, Martinelli F, Dondi G, et al. Efficacy and fertility outcomes of levonorgestrel-releasing intra-uterine system treatment for patients with atypical complex hyperplasia or endometrial cancer: a retrospective study. J Gynecol Oncol. 2019;30:e57. https://doi.org/10.3802/jgo.2019.30.e57.
Park JY, Seong SJ, Kim TJ, et al. Pregnancy outcomes after fertility-sparing management in young women with early endometrial cancer. Obstet Gynecol. 2013;121:136–42. https://doi.org/10.1097/aog.0b013e31827a0643.
Leone Roberti Maggiore U, Khamisy-Farah R, Bragazzi NL, et al. Fertility-sparing treatment of patients with endometrial cancer: a review of the literature. J Clin Med. 2021;10(20). https://doi.org/10.3390/jcm10204784.
Koskas M, Uzan J, Luton D, et al. Prognostic factors of oncologic and reproductive outcomes in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma: systematic review and meta-analysis. Fertil Steril. 2014;101:785–94. https://doi.org/10.3390/jcm10204784.
Elizur SE, Beiner ME, Korach J, et al. Outcome of in vitro fertilization treatment in infertile women conservatively treated for endometrial adenocarcinoma. Fertil Steril. 2007;88:1562–7. https://doi.org/10.1016/j.fertnstert.2007.01.058.
Fujimoto A, Ichinose M, Harada M, et al. The outcome of infertility treatment in patients undergoing assisted reproductive technology after conservative therapy for endometrial cancer. J Assist Reprod Genet. 2014;31:1189–94. https://doi.org/10.1007/s10815-014-0297-x.
Han AR, Kwon YS, Kim DY, et al. Pregnancy outcomes using assisted reproductive technology after fertility-preserving therapy in patients with endometrial adenocarcinoma or atypical complex hyperplasia. Int J Gynecol Cancer. 2009;19:147–51. https://doi.org/10.1111/IGC.0b013e31819960ba.
Kim MJ, Choe SA, Kim MK, et al. Outcomes of in vitro fertilization cycles following fertility-sparing treatment in stage IA endometrial cancer. Arch Gynecol Obstet. 2019;300:975–80. https://doi.org/10.1007/s00404-019-05237-2.
Giorgetti C, Terriou P, Auquier P, et al. Embryo score to predict implantation after in-vitro fertilization: based on 957 single embryo transfers. Hum Reprod. 1995;10:2427–31. https://doi.org/10.1093/oxfordjournals.humrep.a136312.
Gardner DK, Lane M, Stevens J, et al. Blastocyst score affects implantation and pregnancy outcome: towards a single blastocyst transfer. Fertil Steril. 2000;73:1155–8. https://doi.org/10.1016/s0015-0282(00)00518-5.
Zheng X, Chen Y, Yan J, et al. Effect of repeated cryopreservation on human embryo developmental potential. Reprod Biomed Online. 2017;35:627–32. https://doi.org/10.1016/j.rbmo.2017.08.016.
Guo XM, Tanner EJ, Pavone ME. Management and recommendations for future pregnancy in patients with early-stage endometrial cancer: a survey of gynecologic oncologists and reproductive endocrinology and infertility specialists. J Adolesc Young Adult Oncol. 2021. https://doi.org/10.1089/jayao.2020.0228.
Fan Y, Li X, Wang J, et al. Analysis of pregnancy-associated factors after fertility-sparing therapy in young women with early stage endometrial cancer or atypical endometrial hyperplasia. Reprod Biol Endocrinol. 2021;19:118. https://doi.org/10.1186/s12958-021-00808-y.
Kasius A, Smit JG, Torrance HL, et al. Endometrial thickness and pregnancy rates after IVF: a systematic review and meta-analysis. Hum Reprod Update. 2014;20:530–41. https://doi.org/10.1093/humupd/dmu011.
Miwa I, Tamura H, Takasaki A, et al. Pathophysiologic features of “thin” endometrium. Fertil Steril. 2009;91:998–1004. https://doi.org/10.1016/j.fertnstert.2008.01.029.
Inoue O, Hamatani T, Susumu N, et al. Factors affecting pregnancy outcomes in young women treated with fertility-preserving therapy for well-differentiated endometrial cancer or atypical endometrial hyperplasia. Reprod Biol Endocrinol. 2016;14:2. https://doi.org/10.1186/s12958-015-0136-7.
Templeton A, Morris JK, Parslow W. Factors that affect outcome of in-vitro fertilisation treatment. Lancet. 1996;348:1402–6. https://doi.org/10.1016/S0140-6736(96)05291-9.
Sunkara SK, Rittenberg V, Raine-Fenning N, et al. Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles. Hum Reprod. 2011;26:1768–74. https://doi.org/10.1093/humrep/der106.
Nelson SM, Lawlor DA. Predicting live birth, preterm delivery, and low birth weight in infants born from in vitro fertilisation: a prospective study of 144,018 treatment cycles. PLoS Med. 2011;8:e1000386. https://doi.org/10.1371/journal.pmed.1000386.
Chae SH, Shim SH, Lee SJ, et al. Pregnancy and oncologic outcomes after fertility-sparing management for early stage endometrioid endometrial cancer. Int J Gynecol Cancer. 2019;29:77–85. https://doi.org/10.1136/ijgc-2018-000036.
Maheshwari A, McLernon D, Bhattacharya S. Cumulative live birth rate: time for a consensus? Hum Reprod. 2015;30:2703–7. https://doi.org/10.1093/humrep/dev263.
Malizia BA, Hacker MR, Penzias AS. Cumulative live-birth rates after in vitro fertilization. N Engl J Med. 2009;360:236–43. https://doi.org/10.1056/NEJMoa0803072.
Moragianni VA, Penzias AS. Cumulative live-birth rates after assisted reproductive technology. Curr Opin Obstet Gynecol. 2010;22:189–92. https://doi.org/10.1097/GCO.0b013e328338493f.
Toftager M, Bogstad J, Lossl K, et al. Cumulative live birth rates after one ART cycle including all subsequent frozen-thaw cycles in 1050 women: secondary outcome of an RCT comparing GnRH-antagonist and GnRH-agonist protocols. Hum Reprod. 2017;32:556–67. https://doi.org/10.1093/humrep/dew358.
Van Landuyt L, Verpoest W, Verheyen G, et al. Closed blastocyst vitrification of biopsied embryos: evaluation of 100 consecutive warming cycles. Hum Reprod. 2011;26:316–22. https://doi.org/10.1093/humrep/deq338.
Yang R, Niu ZR, Chen LX, et al. Analysis of related factors affecting cumulative live birth rates of the first ovarian hyperstimulation in vitro fertilization or intracytoplasmic sperm injection cycle: a population-based study from 17,978 women in China. Chin Med J (Engl). 2021;134:1405–15. https://doi.org/10.1097/CM9.0000000000001586.
Acknowledgements
We thank all the staffs in the reproductive center of PUTH for their work for this study.
Funding
This study was supported by grants from the CAMS Innovation Fund for Medical Sciences (2019-I2M-5–001) and the National Key Research and Development Program of China (2018YFC1002101).
Author information
Authors and Affiliations
Contributions
YG, XZ, HL, and JQ developed the design of the study. YG and XZ collected the clinical data. XZ drafted the manuscript. YG contributed the data analysis. HL and JQ proofread and revised the manuscript. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Ethics approval
This study was approved by the Ethics Committee of the Peking University Third Hospital (No. IRB00006761-m2021237).
Consent to participate
Approval for a waiver for written consent was obtained from the Ethics Committee of the Peking University Third Hospital due to the retrospective nature of this study.
Consent for publication
This manuscript has not been published or presented elsewhere and is not under consideration by another journal. All study participants provided informed consent and approved it for publication.
Competing interests
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Guo, Y., Zong, X., Li, H. et al. Analysis of IVF/ICSI outcomes in infertile women with early-stage endometrial cancer and atypical endometrial hyperplasia after conservative treatment. J Assist Reprod Genet 39, 1643–1651 (2022). https://doi.org/10.1007/s10815-022-02475-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10815-022-02475-3